Journal Home > Volume 2 , Issue 1
Cancer Innovation 2023, 2(1): 36-51 https://doi.org/10.1002/cai2.60
Review | Open Access | Issue | Published: 01 March 2023

Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022

Show Author's Information Le Zhang1,  Rui Liu1,  Ting Deng1,  Yi Ba1,2 ( )
Department of Gastrointestinal Medical Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China
Keywords:
immunotherapy, pancreatic cancer, chemotherapy, targeted therapy, hepatocellular carcinoma, biliary tract cancer, cholangiocarcinoma
Cite this article:
Zhang L, Liu R, Deng T, et al. Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022. Cancer Innovation, 2023, 2(1): 36-51. https://doi.org/10.1002/cai2.60
Download citation
EndNote(RIS)
BibTeX

713

Views

61

Downloads

Citations

1

Crossref

N/A

WoS

1

Scopus

N/A

CSCD

Abstract Full text About this article

This article summarizes the drug therapy progress of advanced hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular targeted therapy, and immunotherapy, to provide reference information for current clinical treatment and future clinical research, and to better improve prognosis and quality of life in patients with hepatobiliary and pancreatic cancer.


menu
Abstract
Full text
Outline
About this article

Advances in medical treatment of advanced hepatobiliary and pancreatic cancer in 2022

Show Author's information Le Zhang1, Rui Liu1, Ting Deng1, Yi Ba1,2 ( )
Department of Gastrointestinal Medical Oncology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

Abstract

This article summarizes the drug therapy progress of advanced hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular targeted therapy, and immunotherapy, to provide reference information for current clinical treatment and future clinical research, and to better improve prognosis and quality of life in patients with hepatobiliary and pancreatic cancer.

Keywords: immunotherapy, pancreatic cancer, chemotherapy, targeted therapy, hepatocellular carcinoma, biliary tract cancer, cholangiocarcinoma

References(72)

1

Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: a time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020. Cancer Commun. 2021;41(10):1037–48. https://doi.org/10.1002/cac2.12197
DOI Google Scholar
2

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708
DOI Google Scholar
3

Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345–62. https://doi.org/10.1016/S0140-6736(22)01200-4
DOI Google Scholar
4

Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–62. https://doi.org/10.1158/2159-8290.CD-17-0245
DOI Google Scholar
5

Kam AE, Masood A, Shroff RT. Current and emerging therapies for advanced biliary tract cancers. Lancet Gastroenterol Hepatol. 2021;6(11):956–69. https://doi.org/10.1016/S2468-1253(21)00171-0
DOI Google Scholar
6

Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402. https://doi.org/10.1053/j.gastro.2022.03.056
DOI Google Scholar
7

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857
DOI Google Scholar
8

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34. https://doi.org/10.1016/S1470-2045(08)70285-7
DOI Google Scholar
9

Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–73. https://doi.org/10.1016/S0140-6736(18)30207-1
DOI Google Scholar
10

Qin S, Bi F, Gu S, Bai Y, Chen Z, Wang Z, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial. J Clin Oncol. 2021;39(27):3002–11. https://doi.org/10.1200/JCO.21.00163
DOI Google Scholar
11

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66. https://doi.org/10.1016/S0140-6736(16)32453-9
DOI Google Scholar
12

Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63. https://doi.org/10.1056/NEJMoa1717002
DOI Google Scholar
13

Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–96. https://doi.org/10.1016/S1470-2045(18)30937-9
DOI Google Scholar
14

Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterol Hepatol. 2021;6(7):559–68. https://doi.org/10.1016/S2468-1253(21)00109-6
DOI Google Scholar
15

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90. https://doi.org/10.1016/S1470-2045(21)00604-5
DOI Google Scholar
16

Qin S, Chan LS, Gu S, Bai Y, Ren Z, Lin X, et al. LBA35 camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase Ⅲ trial. Ann Oncol. 2022;33:S1401–2. https://doi.org/10.1016/j.annonc.2022.08.032
DOI Google Scholar
17

Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379. https://doi.org/10.1200/JCO.2022.40.4_suppl.379
DOI Google Scholar
18

Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6(11):e204564. https://doi.org/10.1001/jamaoncol.2020.4564
DOI Google Scholar
19

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–52. https://doi.org/10.1016/S1470-2045(18)30351-6
DOI Google Scholar
20

Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571–80. https://doi.org/10.1016/S1470-2045(20)30011-5
DOI Google Scholar
21

Edeline J, Merle P, Fang W, Assenat E, Pan H, Rimassa L, et al. Clinical outcomes associated with tislelizumab in patients (pts) with advanced hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (SOR) or lenvatinib (LEN) in RATIONALE-208. J Clin Oncol. 2022;40(16_suppl):4072. https://doi.org/10.1200/JCO.2022.40.16_suppl.4072
DOI Google Scholar
22

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase Ⅲ trial. J Clin Oncol. 2020;38(3):193–202. https://doi.org/10.1200/JCO.19.01307
DOI Google Scholar
23

Finn RS, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, et al. Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the randomized, phase 3 KEYNOTE-240 study. J Clin Oncol. 2021;39(15_suppl):4072. https://doi.org/10.1200/JCO.2021.39.15_suppl.4072
DOI Google Scholar
24

Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. J Clin Oncol. 2022;40(4_suppl):383. https://doi.org/10.1200/JCO.2022.40.4_suppl.383
DOI Google Scholar
25

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745
DOI Google Scholar
26

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–73. https://doi.org/10.1016/j.jhep.2021.11.030
DOI Google Scholar
27

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 2021;22(7):977–90. https://doi.org/10.1016/S1470-2045(21)00252-7
DOI Google Scholar
28

Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. https://doi.org/10.1016/S1470-2045(22)00326-6
DOI Google Scholar
29

Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–70. https://doi.org/10.1200/JCO.20.00808
DOI Google Scholar
30

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, et al. LBA34 primary results from the phase Ⅲ LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2022;33:S1401. https://doi.org/10.1016/j.annonc.2022.08.031
DOI Google Scholar
31

Hechtman JF, Liu W, Sadowska J, Zhen L, Borsu L, Arcila ME, et al. Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). Mod Pathol. 2015;28(8):1123–9. https://doi.org/10.1038/modpathol.2015.57
DOI Google Scholar
32

Javle M, Borad MJ, Azad NS, Kurzrock R, Abou-Alfa GK, George B, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021;22(9):1290–300. https://doi.org/10.1016/S1470-2045(21)00336-3
DOI Google Scholar
33

Meric-Bernstam F, Hanna DL, El-Khoueiry AB, Kang YK, Oh DY, Chaves JM, et al. Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): results from a phase I study. J Clin Oncol. 2021;39(3_suppl):299. https://doi.org/10.1200/JCO.2021.39.3_suppl.299
DOI Google Scholar
34

Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, et al. Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022;23(12):1558–70. https://doi.org/10.1016/S1470-2045(22)00621-0
DOI Google Scholar
35

Harding JJ, Cleary JM, Quinn DI, Braña I, Moreno V, Borad MJ, et al. Targeting HER2 (ERBB2) mutation-positive advanced biliary tract cancers with neratinib: results from the phase Ⅱ SUMMIT ‘basket’ trial. J Clin Oncol. 2021;39(3_suppl):320. https://doi.org/10.1200/JCO.2021.39.3_suppl.320
DOI Google Scholar
36

Ohba A, Morizane C, Kawamoto Y, Komatsu Y, Ueno M, Kobayashi S, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): an investigator-initiated multicenter phase 2 study (HERB trial). J Clin Oncol. 2022;40(16_suppl):4006. https://doi.org/10.1200/JCO.2022.40.16_suppl.4006
DOI Google Scholar
37

Lee C, Chon HJ, Cheon J, Lee MA, Im HS, Jang JS, et al. Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14). Lancet Gastroenterol Hepatol. 2023;8(1):56–65. https://doi.org/10.1016/S2468-1253(22)00335-1.
DOI Google Scholar
38

Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by Next-Generation sequencing. Oncologist. 2014;19(3):235–42. https://doi.org/10.1634/theoncologist.2013-0352
DOI Google Scholar
39

Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84. https://doi.org/10.1016/S1470-2045(20)30109-1
DOI Google Scholar
40

Shi GM, Huang XY, Wen TF, Song TQ, Kuang M, Mou HB, et al. Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: updated data from an open-label, single-arm, multicenter phase Ⅱ study (CIBI375A201 study). Cancer Med. 2022;40:e16183. https://doi.org/10.1200/JCO.2022.40.16_suppl.e16183
DOI Google Scholar
41

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, et al. Phase Ⅱ study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–82. https://doi.org/10.1200/JCO.2017.75.5009(2017)
DOI Google Scholar
42

Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, et al. Futibatinib, an irreversible FGFR1–4 inhibitor, in patients with advanced solid tumors harboring FGF/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2022;12(2):402–15. https://doi.org/10.1158/2159-8290.CD-21-0697(2022)
DOI Google Scholar
43

Bahleda R, Italiano A, Hierro C, Mita A, Cervantes A, Chan N, et al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25(16):4888–97. https://doi.org/10.1158/1078-0432.CCR-18-3334
DOI Google Scholar
44

Mazzaferro V, El-Rayes BF, Droz Dit Busset M, Cotsoglou C, Harris WP, Damjanov N, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–71. https://doi.org/10.1038/s41416-018-0334-0
DOI Google Scholar
45

Hollebecque A, Borad M, Goyal L, Schram A, Park JO, Cassier PA, et al. LBA12 efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial. Ann Oncol. 2022;33:S1381. https://doi.org/10.1016/j.annonc.2022.08.006
DOI Google Scholar
46

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. https://doi.org/10.1126/science.aan6733
DOI Google Scholar
47

Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. https://doi.org/10.1200/JCO.19.02105(2019)
DOI Google Scholar
48

Javle MM, Murugesan K, Shroff RT, Borad MJ, Abdel-Wahab R, Schrock AB, et al. Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH). J Clin Oncol. 2019;37(15_suppl):4087. https://doi.org/10.1200/JCO.2019.37.15_suppl.4087
DOI Google Scholar
49

Kim RD, Chung V, Alese OB, El-Rayes BF, Li D, Al-Toubah TE, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888–94. https://doi.org/10.1001/jamaoncol.2020.0930
DOI Google Scholar
50

Ueno M, Ikeda M, Morizane C, Kobayashi S, Ohno I, Kondo S, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–21. https://doi.org/10.1016/S2468-1253(19)30086-X
DOI Google Scholar
51

Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, et al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 2020;147(8):2190–98. https://doi.org/10.1002/ijc.33013
DOI Google Scholar
52

Doki Y, Ueno M, Hsu CH, Oh DY, Park K, Yamamoto N, et al. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med. 2022;11(13):2550–60. https://doi.org/10.1002/cam4.4593
DOI Google Scholar
53

Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, et al. Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer. 2021;149(11):1944–54. https://doi.org/10.1002/ijc.33751
DOI Google Scholar
54

Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, et al. Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase Ⅱ trial. J Immunother Cancer. 2020;8(2):e001240. https://doi.org/10.1136/jitc-2020-001240
DOI Google Scholar
55

Li W, Wang Y, Yu Y, Li Q, Wang Y, Zhang C, et al. Toripalimab in advanced biliary tract cancer. Innovation. 2022;3(4):100255. https://doi.org/10.1016/j.xinn.2022.100255
DOI Google Scholar
56

Chiang NJ, Tan KT, Bai LY, Hsiao CF, Huang CY, Hung YP, et al. Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: A phase Ⅱ T1219 study. Clin Cancer Res. 2022;28(19):4248–57. https://doi.org/10.1158/1078-0432.CCR-22-1152
DOI Google Scholar
57

Oh D-Y, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. J Clin Oncol. 2022;40(4_suppl):378. https://doi.org/10.1200/JCO.2022.40.4_suppl.378
DOI Google Scholar
58

Taieb J, Carrato B, Westphalen D, Melisi G, Prager T, Macarulla Mercade ABC, et al. First-line (1L) full dose (f) and modified (m) FOLFIRINOX and gemcitabine+nab-paclitaxel (GN) treatment (tx) for metastatic pancreatic adenocarcinoma (mPAC) patients (pts) in routine clinical practice across Europe. Ann Oncol. 2018;29: viii244–5. https://doi.org/10.1093/annonc/mdy282.106
DOI Google Scholar
59

Carrato A, Pazo-Cid R, Macarulla T, Gallego J, Jiménez-Fonseca P, Rivera F, et al. Sequential nab-paclitaxel/gemcitabine followed by modified FOLFOX for first-line metastatic pancreatic cancer: the SEQUENCE trial. J Clin Oncol. 2022;40:4022. https://doi.org/10.1200/JCO.2022.40.16_suppl.4022
DOI Google Scholar
60

de la Fouchardiere C, Hammel P, Launay S, Vienot A, Raimbourg J, Perrier H, et al. 1566TiP PRODIGE 65—UCGI 36—GEMPAX: a unicancer phase Ⅲ randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in metastatic pancreatic ductal adenocarcinoma. Ann Oncol. 2020;31:S954–55. https://doi.org/10.1016/j.annonc.2020.08.2049
DOI Google Scholar
61

Wang L, Qin S, Zhou Y, Zhang S, Sun X, Chen Z, et al. LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase Ⅲ trial (HR-IRI-APC). Ann Oncol. 2022;33:S1426. https://doi.org/10.1016/j.annonc.2022.08.063
DOI Google Scholar
62

Bekaii-Saab TS, Spira AI, Yaeger R, Buchschacher GL, McRee AJ, Sabari JK, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clin Oncol. 2022;40:519. https://doi.org/10.1200/JCO.2022.40.4_suppl.519
DOI Google Scholar
63

Qin S, Bai Y, Wang Z, Chen Z, Xu R, Xu J, et al. Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: a prospective, randomized-controlled, double-blinded, multicenter, and phase Ⅲ clinical trial. J Clin Oncol. 2022;40:LBA4011. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA4011
DOI Google Scholar
64

Bear AS, Vonderheide RH, O'Hara MH. Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell. 2020;38(6):788–802. https://doi.org/10.1016/j.ccell.2020.08.004
DOI Google Scholar
65

Gössling GCL, Zhen DB, Pillarisetty VG, Chiorean EG. Combination immunotherapy for pancreatic cancer: challenges and future considerations. Expert Rev Clin Immunol. 2022;18(11):1173–86. https://doi.org/10.1080/1744666X.2022.2120471
DOI Google Scholar
66

Bockorny B, Grossman JE, Hidalgo M. Facts and hopes in immunotherapy of pancreatic cancer. Clin Cancer Res. 2022;28(21):4606–17. https://doi.org/10.1158/1078-0432.CCR-21-3452
DOI Google Scholar
67

Zhu YH, Zheng JH, Jia QY, Duan ZH, Yao HF, Yang J, et al. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment. Cell Oncol. 2023;46:17–48. https://doi.org/10.1007/s13402-022-00741-1
DOI Google Scholar
68

Jin G, Guo S, Xu J, Liu R, Liang Q, Yang Y, et al. A multicenter, randomized, double-blind phase Ⅲ clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01). J Clin Oncol. 2022;40:TPS4189. https://doi.org/10.1200/JCO.2022.40.16_suppl.TPS4189
DOI Google Scholar
69

Fu Q, Chen Y, Huang D, Guo C, Zhang Q, Li X, et al. Randomized phase Ⅲ study of sintilimab in combination with modified folfrinox versus folfrinox alone in patients with metastatic and recurrent pancreatic cancer in China: the CISPD3 trial. J Clin Oncol. 2022;40:560. https://doi.org/10.1200/JCO.2022.40.4_suppl.560
DOI Google Scholar
70

Reiss KA, Mick R, Teitelbaum UR, O'Hara MH, Schneider CJ, Massa RC, et al. A randomized phase Ib/Ⅱ study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC). J Clin Oncol. 2022;40:4021. https://doi.org/10.1200/JCO.2022.40.16_suppl.4021
DOI Google Scholar
71

Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450–6. https://doi.org/10.1038/s41586-021-03362-0
DOI Google Scholar
72

Casadei-Gardini A, Rimini M, Rimassa L, Burgio V, Kudo M, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international study. J Clin Oncol. 2022;40:4069. https://doi.org/10.1200/JCO.2022.40.16_suppl.4069
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 19 January 2023
Accepted: 14 February 2023
Published: 01 March 2023
Issue date: February 2023

Copyright

© 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on behalf of Tsinghua University Press.

Acknowledgements

ACKNOWLEDGMENTS

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Return